Press Room


    Press Release - February 25, 2003

    Pheromone Sciences Enters Advanced Dairy Testing

    Toronto, Ontario (February 25, 2003) -- Pheromone Sciences Corp (TSX-V:PHS), is pleased to announce the commencement of advanced testing of its proprietary sensing technology for large animal breeding at the Ontario Veterinary College, University of Guelph, under the direction of Dr. Walter Johnson. This testing is designed to generate core data required to fully adapt the Company's PSC Fertility Monitor for use in detecting hormone and ovulation patterns in dairy cows. This work is scheduled to be completed at the end of Q3.

    As part of this effort, the company is pleased to announce the engagement of Dr. Linda Rhodes VMD, PhD as consultant to help design and manage the best possible clinical program for the animal breeding technology. Within this ongoing program, the Company looks to generate efficacy and economic data for use by the target market. Dr Rhodes' experience combines over 23 years in dairy cattle veterinary practice, research in reproductive physiology, and human and animal drug discovery and development. Dr. Rhodes has experience with designing and executing clinical trials and leading product development teams in the veterinary pharmaceutical industry.

    "We are very excited about this next stage of the development process for our PSC Fertility Monitor technology and continue tracking toward completion of this agricultural program next year." said Christopher Neuman, President and CEO of Pheromone Sciences.

    This novel program is based on the same core technology employed within the FDA approved PSC Fertility Monitor for human use. Successful completion of the agricultural program next year would create a non-invasive, safe and easy to use fertility and ovulation detection device for use in cattle breeding operations. Currently, some US$400 million is lost each year in North America due to timing issues in breeding dairy herds.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

    INVESTOR CONTACT Lorne Woods 1-(800) 937-3095


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News